Seocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma
Seocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma. Efficacy of Seocalcitol (EB 1089) Enteric-Coated Capsules (5 ug) or Placebo in Prolonging Time to Relapse Following Intended Curative Resection or Percutaneous Ablative Treatment for Hepatocellular Carcinoma
Sponsor: LEO Pharma
Listed as NCT00051545, this PHASE3 trial focuses on Liver Neoplasms and remains terminated or withdrawn. Sponsored by LEO Pharma, it has been updated 7 times since 1999, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Mar 2025 — Sep 2025 [monthly]
Terminated PHASE3
-
Sep 2024 — Mar 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE3
First recorded
Nov 1999
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- LEO Pharma
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Barcelona, Spain
- • Edinburgh, United Kingdom
- • Metz, France
- • Milan, Italy
- • Toronto, Canada